A serious adverse reaction or the suspicion of such a reaction that has occurred unexpectedly during a clinical trial. A SUSAR may or may not be dose-related. In the EU, reporting of SUSARs is mandatory while in the US reporting is mandatory during clinical trials but not during clinical care.